ClinicalTrials.gg
RecruitingNCT04926597EFFORT IIUpdated Nov 20, 2024

Effect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery

An interventional study of nutritional supplement and individualized nutritional guidelines in Malnutrition, sponsored by Philipp Schuetz. Recruiting at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Philipp Schuetz · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Malnutrition with a site in Switzerland — 6 open to participants now, 6 under way, 1 of them phase 3. Malnutrition · Switzerland.

Planned enrollment
2nd of 16
1,200 · median 154
Started
2021
with 3 others
No phase
10 of 25
4 open now
Registered
16th of 25
by date
Lead sponsor
2 of 25
Philipp Schuetz

Among the 25 studies in Malnutrition with a site in Switzerland, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 with no phase, and was the 16th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

6 of the 25 studies in Malnutrition with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Malnutrition with a site in Switzerland, or all of them as a file.
02

Study summary

This study is to compare the sustained post-discharge nutritional support to reach individual energy and protein goals to usual care home nutrition in medical patients at nutritional risk.

Read the detailed description

Malnutrition is a strong and independent long-term risk factor for mortality, rehospitalisation and functional decline, particularly in the elderly, polymorbid medical patient population. The randomized-controlled Effect of early nutritional support on Frailty, Functional Outcomes and Recovery of malnourished medical inpatients Trial (EFFORT, Lancet 2019) included 2028 patients in eight Swiss hospitals and found that nutritional support during the inhospital stay reduces very efficiently the risk for complications and mortality with numbers needed to treat (NNT) of 23 and 37, respectively.

Yet, the nutritional intervention was not continued after hospital discharge of patients and long-term follow-up data of patients showed a lack of sustained effect of the initial nutritional support strategy. There is a current lack of trial data investigating whether long-term use of nutritional support has a sustained effect on clinical outcomes in this patient population. This study is to compare the continuous use of nutritional support with the use of approved oral nutritional supplements to reach protein and energy goals and to analyze whether medical patients at nutritional risk show a sustained benefit from long-term nutritional support after hospital discharge, and why and how nutritional support affects the course of disease from a mechanistic physio-pathological standpoint.

03

Conditions studied

  • Malnutrition

Keywords

  • Nutritional Support
  • Oral Nutritional Supplements
  • Frailty
  • Mortality
  • Morbidity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Adult (age ≥18 years), medical patients
  • Nutritional risk screening using the Nutritional Risk Screening (NRS): total score ≥3 points consisting of ≥1 points for impairment of the nutritional status [weight loss >5% in 3 month or food intake of 50-75% in the last week before hospital admission] plus ≥1 for the severity of the disease (i.e., cancer, chronic kidney disease, chronic heart failure, ) and other chronic diseases according to the definition of the "National Center for Chronic Disease Prevention and Health Promotion": Chronic diseases are defined broadly as conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both .

Exclusion criteria

Exclusion Criteria:

  • after surgery
  • unable to ingest oral nutrition
  • need for long-term nutrition,
  • terminal condition
  • acute pancreatitis or acute liver failure
  • patients discharged to a nursing home
  • patients unlikely to comply with nutritional support treatment (e.g., dementia)
  • COVID-Hospitalisation requiring intensive care
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Intervention group: individualized nutritional support

    Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed

    Dietary Supplement: nutritional supplement · Other: individualized nutritional guidelines

  • Other
    Control group: general information on healthy food habits

    Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up

    Other: general nutritional information

Interventions

  • Dietary supplementnutritional supplement

    daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).

  • Otherindividualized nutritional guidelines

    nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.

  • Othergeneral nutritional information

    general information about health food behavior upon hospital discharge

06

What researchers measure

Primary outcomes

  1. time to death from any cause (i.e., all-cause mortality)

    time to death from any cause (i.e., all-cause mortality)

    Time frame: Enrollment to 3 years

Secondary outcomes

  1. Time to non-elective hospital readmission after discharge from the index hospital stay

    Time to non-elective hospital readmission after discharge from the index hospital stay

    Time frame: assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)]

  2. Time to the first major complication

    time to the first major complication including death, bacterial infection with need for antibiotic treatment, major cardiovascular event (i.e., stroke, intracranial bleeding, cardiac arrest, myocardial infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events (including hemorrhage, intestinal perforation, acute pancreatitis)

    Time frame: assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)]

  3. Changes in functional status measured by the Barthel's index

    Changes in functional status measured by the Barthel's index (scores range from 0 to 100, with higher scores indicating better functional status)

    Time frame: assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)]

  4. Changes in quality of life measured with the European Quality of Life 5 Dimensions index (German Version, EQ-5D index)

    Changes in quality of life measured with the European Quality of Life 5 Dimensions index (German Version, EQ-5D index values range from 0 to 1, with higher scores indicating better quality of life)

    Time frame: assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)]

  5. Changes in quality of life measured with the visual-analogue scale (EQ-5D VAS)

    Changes in quality of life measured with the visual-analogue scale (EQ-5D VAS) (scores range from 0 to 100, with higher scores indicating better health status).

    Time frame: assessed from Day 0 (study enrolment), then every 6 month through phone calls up to end of trial (approx 3 years)]

Other outcomes

  1. Change in body weight

    Change in body weight

    Time frame: assessed from Day 0 (study enrolment), then at 3, 6 and 12 months by home visits

  2. Change in calf circumference to assess muscle mass

    Change in calf circumference to assess muscle mass

    Time frame: assessed from Day 0 (study enrolment), then at 3, 6 and 12 months by home visits

  3. Change in bioelectrical impedance analysis (BIA) to assess body composition

    Change in bioelectrical impedance analysis (BIA) to assess body composition

    Time frame: assessed from Day 0 (study enrolment), then at 3, 6 and 12 months by home visits

  4. Change in hand grip by means of handgrip strength through dynamometry (North Coast Medical Exacta™ Hydraulic Hand Dynamometer) to assess muscle strength

    Change in hand grip by means of handgrip strength through dynamometry (North Coast Medical Exacta™ Hydraulic Hand Dynamometer) to assess muscle strength

    Time frame: assessed from Day 0 (study enrolment), then at 3, 6 and 12 months by home visits

07

Study locations

10 of 18 sites recruiting
  • Hospital Universitari Vall Hebron de Barcelona
    Barcelona, Spain
    Recruiting
  • Hospital Universitario de Getafe
    Getafe, Spain
    Recruiting
  • Complejo AComplejo Asistencial Universitario de León
    León, Spain
    Recruiting
  • Hospital U. Gregorio Marañón de Madrid
    Madrid, Spain
    Recruiting
  • Hospital Universitario Regional de Málaga
    Málaga, Spain
    Recruiting
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Spain
    Recruiting
  • Spital Zofingen
    Zofingen, Aargau 4800, Switzerland
    Completed

    Not enrolling at this site.

  • Spital Emmental Burgdorf
    Burgdorf, Bern 3400, Switzerland
    Completed

    Not enrolling at this site.

  • Spital Thun
    Thun, Bern 3600, Switzerland
    Recruiting
  • Spital Lachen
    Lachen, Schwyz 8853, Switzerland
    Recruiting
  • Kantonsspital Münsterlingen
    Münsterlingen, Thurgau 8596, Switzerland
    Recruiting
    • Vojtech Pavlicek, Dr. med. · Contact
    • Vojtech Pavlicek, Dr. med. · Principal investigator
  • Kantonsspital Aarau, University Department of Internal Medicine
    Aarau, 5001, Switzerland
    Recruiting
    • Philipp Schuetz, Prof. Dr. med. · ContactPhilipp.Schuetz@unibas.ch · +41 (0) 62 838 9524
    • Philipp Schuetz, Prof. Dr. med. · Principal investigator
    • Beat Mueller, Prof. Dr. med · Sub investigator
    • Nina Kägi-Braun, Dr. med. · Sub investigator
    • Pascal Tribolet · Sub investigator
    • Manuela Deiss · Sub investigator
    • T Ehmann, Dr. med. · Sub investigator
    • Carla Wunderle, PhD · Sub investigator
  • Bern University Hospital, Department of General Internal Medicine
    Bern, Switzerland
    Completed

    Not enrolling at this site.

  • Kantonsspital Lucerne, Department of Internal Medicine
    Lucerne, Switzerland
    Completed

    Not enrolling at this site.

  • Kantonsspital Sankt Gallen
    Sankt Gallen, 9007, Switzerland
    Completed

    Not enrolling at this site.

  • Klinik Hirslanden Zürich
    Zürich, 8032, Switzerland
    Completed

    Not enrolling at this site.

  • Stadtspital Zürich
    Zürich, 8063, Switzerland
    Completed

    Not enrolling at this site.

  • Universitätsspital Zürich
    Zürich, 8091, Switzerland
    Completed

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.

Of 393 non-industry interventional studies with no phase under Malnutrition, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 64 months is above that.

Counting every sponsor, half of 419 studies reached it within 22 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 15, 2021
StartActual
Aug 5, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04926597
Lead sponsor
Philipp Schuetz
Responsible party
Philipp Schuetz (Prof. Dr. med., Kantonsspital Aarau) — Sponsor-investigator
First posted
Jun 15, 2021
Start date
Aug 5, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 20, 2024

Study contacts

Philipp Schuetz, Prof. Dr. med.
Contact
Philipp.Schuetz@unibas.ch
+41 (0) 62 838 9524
Philipp Schuetz, Prof. Dr. med.
principal investigator · Kantonsspital Aarau, University Department of Internal Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion